067080 — Dae Hwa Pharm Co Share Price
0.000.00%
Last trade - 00:00- KR₩181bn
- KR₩289bn
- KR₩141bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.47 | ||
| Price to Tang. Book | 4.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.28 | ||
| EV to EBITDA | 38.99 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.82% | ||
| Return on Equity | -1.52% | ||
| Operating Margin | 1.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 114,609.57 | 109,345.86 | 117,158.83 | 131,911.69 | 141,359.22 | n/a | n/a | 5.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +144.75 | n/a | n/a | -16.04 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DAE HWA PHARM CO.,LTD. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Company’s products include skeletal muscle relaxants, gastro-intestinal drugs, corticosteroids, antihistamines, cardiovascular drugs, drugs for liver diseases, vitamins, tonics, antibiotics, injections, topical drugs, anti-inflammatory enzymes, analgesics, antipyretics, plaster, cough suppressants, expectorants and mucolytics, drugs for hemorrhoid disease and other prescription drugs, as well as over-the-counter (OTC) drugs. The Company distributes its products within domestic market and to overseas markets. On August 22, 2013, it acquired a certain shares of a Korea-based company, which is mainly engaged in the manufacture of medicine raw materials and development of medical devices. After the transaction, the Company held a 100% stake of the Korea-based company.
Directors
- Han Gu Lee CHM (70)
- Gwon Seok Han MDR (60)
- Byeong Yun Hwang MDR (58)
- Yeong Wu Cho OTH (51)
- Hyo Won Kang OTH (54)
- Jae Hyeong Kim OTH (56)
- Eun Seok Kim DRC (37)
- Gyeong Yeol Baek NID (61)
- Jun Bo Lee NID (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 19th, 1989
- Public Since
- February 14th, 2003
- No. of Shareholders
- 15,084
- No. of Employees
- 424
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 17,516,650
- Address
- 495, Hanu-ro, Hoengseong-eup, HOENGSEONG, 25228
- Web
- https://www.dhpharm.co.kr/html/
- Phone
- +82 25866451
- Auditors
- Daejoo Accounting Corp.
Upcoming Events for 067080
Q2 2024 Dae Hwa Pharm Co Ltd Earnings Release
Similar to 067080
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
Ahn-Gook Pharmaceutical Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
What is the Dae Hwa Pharm Co share price?
As of Today at 19:06 UTC, shares in Dae Hwa Pharm Co are trading at KR₩10,310. This share price information is delayed by 15 minutes.
How has the Dae Hwa Pharm Co share price performed this year?
Shares in Dae Hwa Pharm Co last closed at KR₩10,310 and the price had moved by +8.76% over the past 365 days. In terms of relative price strength the Dae Hwa Pharm Co share price has outperformed the FTSE Developed Asia Pacific Index by +13.52% over the past year.
What are the analyst and broker recommendations for Dae Hwa Pharm Co?
There is no consensus recommendation for this security.
What is the Dae Hwa Pharm Co dividend yield?
The Dae Hwa Pharm Co dividend yield is 1.45% based on the trailing twelve month period.
Does Dae Hwa Pharm Co pay a dividend?
Last year, Dae Hwa Pharm Co paid a total dividend of KR₩150, and it currently has a trailing dividend yield of 1.45%.Looking ahead, the next dividend pay date is 2024-04-26.
When does Dae Hwa Pharm Co next pay dividends?
We do not have data on when Dae Hwa Pharm Co is to next pay dividends. The historic dividend yield on Dae Hwa Pharm Co shares is currently 1.45%.
How do I buy Dae Hwa Pharm Co shares?
To buy shares in Dae Hwa Pharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dae Hwa Pharm Co?
As of the previous close price of KR₩10,310, shares in Dae Hwa Pharm Co had a market capitalisation of KR₩181bn.
Where are Dae Hwa Pharm Co shares listed?
Here are the trading details for Dae Hwa Pharm Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 067080
What kind of share is Dae Hwa Pharm Co?
Based on an overall assessment of its quality, value and momentum Dae Hwa Pharm Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dae Hwa Pharm Co share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Dae Hwa Pharm Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dae Hwa Pharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -5.85%.
As of the last closing price of KR₩10,310, shares in Dae Hwa Pharm Co were trading +4.55% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dae Hwa Pharm Co PE Ratio?
The Dae Hwa Pharm Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩10,310.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dae Hwa Pharm Co?
Dae Hwa Pharm Co's management team is headed by:
- Han Gu Lee - CHM
- Gwon Seok Han - MDR
- Byeong Yun Hwang - MDR
- Yeong Wu Cho - OTH
- Hyo Won Kang - OTH
- Jae Hyeong Kim - OTH
- Eun Seok Kim - DRC
- Gyeong Yeol Baek - NID
- Jun Bo Lee - NID